Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 6Breast 6Tumor-Agnostic 4Sarcoma 4Other hematologic neoplasm 3Gynecologic 3Genitourinary 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Recurrence 1Neoplasms 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × STA 9090 × Thoracic × Clear all
NCT01590160 2019-11-13

MESO-02

University College, London

Phase 1/2 Completed
27 enrolled
Other solid neoplasmThoracic

Lung Cancer - Malignant Pleural Mesothelioma

NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
25 enrolled 8 charts
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT02261805 2018-04-23

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Georgetown University

Phase 1/2 Terminated
11 enrolled 7 charts
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT01798485 2016-07-01

Galaxy 2

Synta Pharmaceuticals Corp.

Phase 3 Terminated
696 enrolled 28 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01562015 2015-05-20

CHIARA

Synta Pharmaceuticals Corp.

Phase 2 Completed
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 2 Completed
113 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡